RYAM Schedules Second Quarter 2025 Earnings Release
Earnings Release Announcement: Rayonier Advanced Materials (RYAM) will release its Q2 2025 earnings on August 5, 2025, after market close, followed by a conference call on August 6 at 9:00 a.m. ET.
Company Overview: RYAM is a leader in cellulose-based technologies with diverse applications, generating $1.6 billion in revenue in 2024, and operates manufacturing facilities in the U.S., Canada, and France.
Trade with 70% Backtested Accuracy
Analyst Views on RYAM
About RYAM
About the author
Multiple Material Stocks Receive 'F' EPS Revision Grades, Indicating Weak Earnings Momentum
- EPS Revision Grade Analysis: As the earnings season approaches, an analysis reveals that several mid to low cap material stocks have received an 'F' EPS revision grade, indicating significant downward pressure on future earnings expectations, which may lead to decreased investor confidence.
- List of Affected Companies: Companies such as American Battery Technology Company (ABAT), Algoma Steel Group Inc. (ASTL), and Eastman Chemical Company (EMN) have all received an 'F' grade, highlighting serious challenges in their earnings momentum.
- Market Impact Assessment: The poor EPS revision grades of these companies could adversely affect their stock performance, prompting investors to carefully assess associated risks, especially during the earnings season when market sensitivity to earnings is heightened.
- Industry Outlook: With the earnings season underway, the overall performance of the materials sector may be dragged down by these low-rated companies, leading investors to seek out better-performing firms within the industry for potential investment opportunities.
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
Rayonier Appoints Scott Sutton as New CEO Effective January 5
- Leadership Change: Rayonier Advanced Materials announced the appointment of Scott Sutton as CEO and President effective January 5, succeeding DeLyle Bloomquist, whose planned retirement ensures leadership continuity and ongoing strategic initiatives.
- Experienced Successor: Sutton brings over 30 years of industry experience, having previously served as CEO and President of Olin Corp, and his extensive management background is expected to provide new growth opportunities for the company.
- Market Reaction: Following the leadership announcement, Rayonier Advanced Materials' stock closed down 0.51% at $5.86 on the New York Stock Exchange, indicating market caution regarding the company's future direction.
- Strategic Support: Bloomquist will remain as an advisor to support the leadership transition and ongoing strategic initiatives, aiming to ensure stability and continued growth during this period of change.
Rayonier Advanced Materials Appoints Scott M. Sutton as CEO Effective January 5, 2026
- Leadership Change: Rayonier Advanced Materials has appointed Scott M. Sutton as CEO and President, effective January 5, 2026, bringing over 30 years of global leadership experience in the chemicals and materials sectors, which is expected to enhance the company's operational excellence.
- Strategic Continuity: Sutton succeeds DeLyle W. Bloomquist, who will serve as an advisor during the transition, ensuring leadership continuity and supporting ongoing strategic initiatives that aim to strengthen RYAM's competitive positioning in the market.
- Performance Incentive Plan: The company will grant Sutton 750,000 performance share units (PSUs) with a three-year performance period and a target price of $30, potentially reaching up to $45, designed to motivate him to drive company performance and shareholder value.
- Market Positioning: With $1.6 billion in revenue generated in 2024, Sutton's appointment is anticipated to accelerate RYAM's strategic development in the biomaterials sector, further solidifying its leadership position in global markets.
Significant Options Activity on Tuesday: AAPL, MSFT, RYAM
Microsoft Options Volume: Microsoft Corporation (MSFT) has recorded an options volume of 298,519 contracts today, equating to about 29.9 million underlying shares, which is 108.1% of its average daily trading volume over the past month.
High Volume Call Option: The $480 strike call option for MSFT, expiring on November 28, 2025, has seen particularly high activity with 13,043 contracts traded, representing approximately 1.3 million underlying shares.
Rayonier Advanced Materials Options Volume: Rayonier Advanced Materials Inc (RYAM) has reported an options trading volume of 7,097 contracts, which corresponds to about 709,700 underlying shares, or 106% of its average daily trading volume.
Notable RYAM Call Option: The $7 strike call option for RYAM, expiring on January 16, 2026, has also experienced significant trading, with 3,003 contracts exchanged, representing around 300,300 underlying shares.
Three Materials Stocks Set to Surge in Q4
Oversold Stocks Opportunity: The materials sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.
SunCoke Energy Inc: Despite posting better-than-expected quarterly earnings, SunCoke's stock fell 21% over the past month, closing at $6.64 with an RSI of 29.7.
Rayonier Advanced Materials Inc: Rayonier reported weaker-than-expected results, leading to a 22% decline in stock price, which closed at $6.01 and has an RSI of 29.5.
Chemours Co: Chemours experienced a 26% drop in stock price after downbeat earnings, closing at $11.74 with an RSI of 28.8, despite strong demand for its products.
Multiple Material Stocks Receive 'F' EPS Revision Grades, Indicating Weak Earnings Momentum
- EPS Revision Grade Analysis: As the earnings season approaches, an analysis reveals that several mid to low cap material stocks have received an 'F' EPS revision grade, indicating significant downward pressure on future earnings expectations, which may lead to decreased investor confidence.
- List of Affected Companies: Companies such as American Battery Technology Company (ABAT), Algoma Steel Group Inc. (ASTL), and Eastman Chemical Company (EMN) have all received an 'F' grade, highlighting serious challenges in their earnings momentum.
- Market Impact Assessment: The poor EPS revision grades of these companies could adversely affect their stock performance, prompting investors to carefully assess associated risks, especially during the earnings season when market sensitivity to earnings is heightened.
- Industry Outlook: With the earnings season underway, the overall performance of the materials sector may be dragged down by these low-rated companies, leading investors to seek out better-performing firms within the industry for potential investment opportunities.
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
Rayonier Appoints Scott Sutton as New CEO Effective January 5
- Leadership Change: Rayonier Advanced Materials announced the appointment of Scott Sutton as CEO and President effective January 5, succeeding DeLyle Bloomquist, whose planned retirement ensures leadership continuity and ongoing strategic initiatives.
- Experienced Successor: Sutton brings over 30 years of industry experience, having previously served as CEO and President of Olin Corp, and his extensive management background is expected to provide new growth opportunities for the company.
- Market Reaction: Following the leadership announcement, Rayonier Advanced Materials' stock closed down 0.51% at $5.86 on the New York Stock Exchange, indicating market caution regarding the company's future direction.
- Strategic Support: Bloomquist will remain as an advisor to support the leadership transition and ongoing strategic initiatives, aiming to ensure stability and continued growth during this period of change.
Rayonier Advanced Materials Appoints Scott M. Sutton as CEO Effective January 5, 2026
- Leadership Change: Rayonier Advanced Materials has appointed Scott M. Sutton as CEO and President, effective January 5, 2026, bringing over 30 years of global leadership experience in the chemicals and materials sectors, which is expected to enhance the company's operational excellence.
- Strategic Continuity: Sutton succeeds DeLyle W. Bloomquist, who will serve as an advisor during the transition, ensuring leadership continuity and supporting ongoing strategic initiatives that aim to strengthen RYAM's competitive positioning in the market.
- Performance Incentive Plan: The company will grant Sutton 750,000 performance share units (PSUs) with a three-year performance period and a target price of $30, potentially reaching up to $45, designed to motivate him to drive company performance and shareholder value.
- Market Positioning: With $1.6 billion in revenue generated in 2024, Sutton's appointment is anticipated to accelerate RYAM's strategic development in the biomaterials sector, further solidifying its leadership position in global markets.
Significant Options Activity on Tuesday: AAPL, MSFT, RYAM
Microsoft Options Volume: Microsoft Corporation (MSFT) has recorded an options volume of 298,519 contracts today, equating to about 29.9 million underlying shares, which is 108.1% of its average daily trading volume over the past month.
High Volume Call Option: The $480 strike call option for MSFT, expiring on November 28, 2025, has seen particularly high activity with 13,043 contracts traded, representing approximately 1.3 million underlying shares.
Rayonier Advanced Materials Options Volume: Rayonier Advanced Materials Inc (RYAM) has reported an options trading volume of 7,097 contracts, which corresponds to about 709,700 underlying shares, or 106% of its average daily trading volume.
Notable RYAM Call Option: The $7 strike call option for RYAM, expiring on January 16, 2026, has also experienced significant trading, with 3,003 contracts exchanged, representing around 300,300 underlying shares.
Three Materials Stocks Set to Surge in Q4
Oversold Stocks Opportunity: The materials sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.
SunCoke Energy Inc: Despite posting better-than-expected quarterly earnings, SunCoke's stock fell 21% over the past month, closing at $6.64 with an RSI of 29.7.
Rayonier Advanced Materials Inc: Rayonier reported weaker-than-expected results, leading to a 22% decline in stock price, which closed at $6.01 and has an RSI of 29.5.
Chemours Co: Chemours experienced a 26% drop in stock price after downbeat earnings, closing at $11.74 with an RSI of 28.8, despite strong demand for its products.
